# PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation

> **NCT00925782** · PHASE2 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 24 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection
- **DRUG:** Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)

## Key facts

- **NCT ID:** NCT00925782
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925782, "PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00925782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*